Mesalazine Effects in Sporadic Colorectal Adenoma Patients

Sporadic Colorectal Adenoma Clinical Trial

Official title:

Chemopreventive Effects of Mesalazine in Patients at High Risk of Recurrent (Nonfamilial) Colorectal Adenomas

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01894685
• Other study ID #: NL36557.041.11
• Status: Completed
• Phase: Phase 2
• First received: July 3, 2013
• Last updated: December 6, 2015
• Start date: July 2012
• Est. completion date: June 2015

Study information

• Verified date: December 2015
• Source: UMC Utrecht
• Contact: n/a
• Is FDA regulated: No
• Health authority: Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)
• Study type: Interventional

Clinical Trial Summary

Several studies indicate that mesalazine might have a preventive effect on recurrence of adenomas in patients with and without inflammatory bowel disease. As mesalazine has limited adverse effects, it is an attractive candidate for chemoprevention. In this study we aim to investigate the antineoplastic properties of mesalazine in patients with sporadic colorectal adenomas.

Description:

Rationale: Patients with sporadic colorectal adenomatous polyps removed by polypectomy have a high rate of polyp recurrence and carry an increased risk for the development of colorectal carcinoma (CRC). Chemoprevention may lower the rate of adenoma recurrence after polypectomy, thereby reducing the risk of development or death from CRC. Mesalazine is an attractive candidate for chemoprevention, since even during long-term use it has only limited systemic adverse effects and no gastrointestinal toxicity. In a prospective trial a trend towards reduced adenoma recurrence has been observed in high risk patients with a history of at least 3 sporadic colorectal adenomas treated with mesalazine. Identification of biologically relevant antineoplastic properties of mesalazine in patients with sporadic adenomatous polyps will support further investigation of mesalazine as chemopreventive agent against colorectal neoplasia in the sporadic setting. Growth inhibition of colonic epithelial cells through induction of apoptosis and inhibition of proliferation is widely recognized as a potential mechanism for chemoprevention of colorectal cancer. In vivo data suggest that mesalazine exerts pro-apoptotic and anti-proliferative effects on normal colorectal epithelial cells. Furthermore, there is in vitro evidence in CRC cells that mesalazine inhibits Wnt/beta-catenin signalling, an early and common inappropriately activated pathway in colorectal carcinogenesis and molecular target for chemoprevention.

Objective: Evaluate the effects of mesalazine therapy on histologically normal sigmoid and rectal mucosa in patients at high risk of recurrent sporadic colorectal adenomas.

Primary endpoints:

• change in apoptotic index after treatment as compared to placebo

• change in proliferation index and distribution of proliferating cells in crypts after treatment as compared to placebo

Secondary endpoint:

• change in expression of beta-catenin signaling pathway components after treatment as compared to placebo

Study design: double-blind, randomized placebo-controlled study

Study population: 68 patients, aged 50-75 years, who underwent polypectomy within 6 months before study entry, for removal of 2 or more colorectal adenomas irrespective of size and/or 1 colorectal adenoma with at least 1 of the following features: a diameter of at least 1 cm at endoscopy, a proximal localization, high-grade dysplasia or villous histology.

Intervention: Patients will be randomized to receive 3.0 g mesalazine (n=34) or placebo (n=34) once daily for 6 months in a double-blinded way. At baseline and after 6 months of treatment, a sigmoidoscopy will be performed and five biopsies of normal appearing sigmoid and rectal mucosa will be collected.

Main study parameters/endpoints: The effect of treatment with mesalazine on apoptotic and proliferation indices relative to the placebo group.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 74
• Est. completion date: June 2015
• Est. primary completion date: June 2015
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 50 Years to 75 Years

Eligibility

Inclusion Criteria:

• age: 50-75 years

• having undergone complete colonoscopy with polypectomy for removal of

• 2 or more colorectal adenomas, irrespective of size, and/or

• 1 colorectal adenoma:

• of at least 1 cm in diameter and/or

• located proximal to the splenic flexure and/or

• with high-grade dysplasia and/or villous histology

Exclusion Criteria:

• inflammatory bowel disease

• familial colorectal cancer syndrome

• history of colorectal carcinoma

• history of surgery to the large bowel (except appendectomy)

• chronic renal insufficiency

• chronic hepatic insufficiency

• allergy to salicylates

• diabetes mellitus (higher risk for developing renal disease)

• coagulation disorder or anticoagulant use, which cannot be temporarily discontinued (precludes biopsy taking)

• asthma

• prescription use of acetylsalicylic acid or calcium carbasalate (high- and low-dose) or other NSAIDs

• use of medicines which may interact with mesalazine: methotrexate, thiopurines, cyclosporine, coumarin anticoagulants and rifampicin

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention

Related Conditions & MeSH terms

• Adenoma
• Sporadic Colorectal Adenoma

Intervention

Drug:
• Mesalazine
Mesalazine 3 grams, once daily for six months
• Placebo
Placebo 3 grams, once daily for six months

Locations

Country	Name	City	State
Netherlands	University Medical Center Utrecht	Utrecht

Sponsors (1)

Lead Sponsor	Collaborator
UMC Utrecht

Country where clinical trial is conducted

Netherlands, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Apoptotic index	Change in apoptotic index after treatment with mesalazine as compared to placebo	6 months	No
Primary	Proliferation index	Change in proliferation index and distribution of proliferating cells in crypts after treatment with mesalazine as compared to placebo	6 months	No
Secondary	Expression of ß-catenin signaling pathway	Change in expression of ß-catenin signaling pathway components after treatment with mesalazine as compared to placebo	6 months	No